Persistence of treatment and blood pressure control in elderly hypertensive patients treated with different classes of antihypertensive drugs

American Journal of Geriatric Cardiology

Volumn 16, Issue 5, 2007, Pages 280-286

  Borghi, Claudio ^a   Veronesi, Maddalena ^a   Dormi, Ada ^a   Prandin, Maria Grazia ^a   Cosentino, Eugenio ^a   Strocchi, Enrico ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

AGED; ARTICLE; BLOOD PRESSURE; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; PATIENT SELECTION; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SINGLE BLIND PROCEDURE; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; PATIENT SELECTION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 38449083848     PISSN: 10767460     EISSN: 1751715X     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2007.06586.x     Document Type: Article

References (22)

1. The Seventh Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
2. Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28(5):385-407.
3. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as firstline agents. A systematic review and meta-analysis. JAMA. 1997;277:739-745.
4. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10-17.
5. Erdine S, Ari O, Zanchetti A, et al. ESH-ESC guidelines for the management of hypertension. Herz. 2006;31(4):331-338.
6. McCombs JS, Nichol MB, Newman CM, et al. The costs or interrupting antihypertensive drug therapy in a Medicaid Population. Med Care. 1994;32:214-226.
7. Fujita T, Shimamoto K, Wu Z, et al. What are the major challenges in getting patients to the optimal BP goal? Difficulties in educating doctors and patients. Int J Clin Pract Suppl. 2006;(150):20-22.
8. David D.S. Compliance with hypertensive therapy. Hypertension. 2006;48(4):E16.
9. Ambrosioni E, Leonetti G, Pessina AC, et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens. 2000;18(11):1691-1699.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
11. Monane M, Bohn RL, Gurwitz JH, et al. The effects or initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population based study in the elderly. Am J Hypertens. 1997;10:697-704.
12. Okano GJ, Rascati KL, Wilson JP, et al. Patterns or antihypertensive use among patients in the US Department or Defense database initially prescribed an angiotensinconverting enzyme inhibitor or calcium channel blocker. Clin Ther. 1997;19:1433-1444.
13. Jones JK, Gorkin L, Lian JF, et al. Discontinuation or and changes in treatment after start or new courses or antihypertensive drugs: a study or a United Kingdom population. B.M.J. 1995;311:293-295.
14. Black DM, Brand RJ, Greenlick M, et al. Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. J Gerontol. 1987;42:552-557.
15. Bloom B.S. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20(4):671-681.
16. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39(9):1401-1408.
17. Poluzzi E, Strahinja P, Vargiu A, et al. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol. 2005;61(8):603-609.
18. Grimm RH Jr, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med. 1997;157(6):638-648.
19. Dahlof B, Devereux RB, Kjeldsen SE, et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
20. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
21. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertens. 2003;21:1011-1053.
22. Borghi C, Dormi A, D'Addato S, et al. Brisighella Heart Study Working Party. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. Hypertens. 2004;22(9):1707-1716.